Ajanta Pharma earmarks Rs 250 crore capex for FY22

10 May 2021 Evaluate

Ajanta Pharma has earmarked a capex plan of Rs 250 crore for FY22. The company is likely to use the same towards maintenance and some new expansions for the corporate office and some key expansions in the facility. The company operates eight manufacturing facilities in India and Mauritius, including two plants which have been approved by the US Food and Drug Administration (USFDA).

Earlier, the company had earmarked a capex plan of Rs 150 crore for the 2019-20 fiscal. The company had invested Rs 30 crore in the expansion of the corporate office last year, and this year it is going to be in the range of Rs 60-80 crore.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.

Ajanta Pharma Share Price

2638.75 12.50 (0.48%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×